12.12 PM Friday, 29 March 2024
  • City Fajr Shuruq Duhr Asr Magrib Isha
  • Dubai 04:56 06:10 12:26 15:53 18:37 19:52
29 March 2024

Julphar to produce some MSD medicines in region

Published
By Staff

MSD, a leading healthcare company, and Julphar, a UAE-based global pharmaceutical company, have signed a five-year licensing agreement which gives the UAE firm rights to produce, market, distribute and sell certain MSD medicines in UAE, Kuwait, Bahrain, Oman, Qatar and Iraq.

The new partnership will enhance patients’ access to MSD medicines for diabetes, asthma, allergy, pain and inflammation. Both companies will seek the relevant authorities’ approvals on registration and production of the products locally.

“I am proud to announce this landmark agreement between MSD and Julphar – a partnership which will lead to having some MSD products being manufactured in this region for the very first time,” said Ramsey Morad, vice-president, MSD for the Middle East region.

“In light of the exemplary efforts by regional governments to improve their national healthcare systems, MSD is sharing its latest production methods and expertise with Julphar in this joint initiative to support our customers and patients.”

Dr. Ayman Sahli, CEO, Julphar, stated: “This agreement allows a global leader in healthcare to tap into the local know-how and expertise of a regional leader. Manufacturing locally high-quality medications will enhance accessibility and create greater value for all our stakeholders.”

Merck and MSD operate in more than 140 countries and spend more than $8 billion each year on medicines research and development, making it one of the largest contributors to medical research and development among global biopharmaceutical companies.